5
YEARS operating across US · UK · Norway
B
THE BARDO FOUNDATION
ISSUE No 01 · ARENDALSUKA 2026
A STRUCTURED FINANCE BRIEF · CHILDHOOD CANCER
Childhood cancer is a solvable problem we are failing to fund.
THESISThe system fails before the science does. Capital, not discovery, is the constraint.
INSTRUMENTThe Yellow Bond · structured finance for pediatric oncology.
PUBLISHERThe Bardo Foundation · 501(c)(3)
DISTRIBUTED ATArendalsuka · Arendal, Norway · 2026
01 / 10
THE PROBLEM · 01
The system failsbefore the science does.
Survival has improved at the margin; progress has stalled in high-risk pediatric cancers where it matters most. Childhood cancer remains a leading cause of disease-related death in children across the developed world.
Breakthrough science exists. It dies in the funding gap. Small patient populations limit commercial incentives. Capital does not flow because risk and return are structurally misaligned.
BillionsIN LOST GDP AND TAX REVENUE ANNUALLY
THE FUNDING GAP
Science exists. Capital does not reach it.
- 01Drug development timelines are long and uncertain.
- 02Returns fragment across multiple stakeholders.
- 03Pediatric indications sit secondary to adult markets.
- 04Traditional models rely on grants and philanthropy alone.
- 05No scalable financial structure exists to absorb the risk.
02 / 10
THE SOLUTION · 02
A STRUCTURED FINANCE INSTRUMENT
Introducingthe Yellow Bond.
A scaled financing vehicle for childhood cancer research. Structured credit applied to pediatric oncology. Built to mobilize institutional capital and move this field from one-off donations to systematic funding flows.
STEP 01 · CAPITAL
Bond issuance
Institutional investors; philanthropic guarantee pool; blended-finance structure.
STEP 02 · DEPLOYMENT
Research portfolio
Diversified pediatric oncology; cross-stage, cross-geography; risk-mitigated by structure.
STEP 03 · RETURNS
Cash-flow streams
Royalties from therapies; milestone payments from industry; strategic asset monetization.
STEP 04 · RECYCLE
Self-reinforcing
Capital recirculates; philanthropy layers in first-loss; research compounds over time.
03 / 10
Why it works · six structural features.
THE FEATURES · 03
01
Diversification
Reduces single-asset failure risk. Research is a portfolio problem and we finance it as one.
02
Structured vehicles
Create predictable return profiles and tranched risk appropriate for different allocators.
03
Institutional mandates
Investors participate within existing rules. No special mandate required to allocate.
04
Recyclable capital
Funding recirculates through royalties and milestone payments. Not one-time giving.
05
Systematic flows
Replaces fragmented ad-hoc grants with disciplined, repeatable deployment.
06
Sustainable system
Pediatric research becomes self-reinforcing rather than donation-dependent.
04 / 10
THE AUDIENCE · 04
Who thisunlocks.
$100M+
CAPITAL UNLOCKED AT PILOT SCALE
SOVEREIGN & GOV
Ministries and sovereign funds seeking high-leverage social finance vehicles.
INSTITUTIONAL
Pension funds, insurers, asset managers with ESG and impact mandates.
PHILANTHROPIC
Foundations willing to provide first-loss and catalytic capital layers.
SCIENTIFIC
Leading pediatric oncology institutions. Industry partners for royalties.
05 / 10
TODAY · STATUS QUO
Fragmented and inefficient.
- 01Isolated projects and competing appeals
- 02Donation-dependent cash flows
- 03Ad-hoc allocation; no portfolio view
- 04Slow translation from lab to patient
- 05No access to institutional capital pools
COMPETITION · 05 · THE INCUMBENT MODEL
FUTURE · THE YELLOW BOND
Structured and scalable.
- 01Coordinated pediatric oncology portfolios
- 02Capital markets participation at scale
- 03Tranched risk and recyclable flows
- 04Accelerated translation to patients
- 05Institutional allocators participate within mandate
FROM FRAGMENTATION TO INFRASTRUCTURE
THE
SHIFTBARDO · 2026
SHIFTBARDO · 2026
06 / 10
ORIGIN STORY · 06
WHO WE ARE
The BardoFoundation.
A 501(c)(3) operating at the intersection of science, capital markets, and policy. Built to translate structured-finance discipline into research funding that actually reaches children.
Founded and led by senior structured finance practitioners; guided by pediatric oncologists; informed by institutional allocators. Not another awareness campaign.
7
COUNTRIES funded to date
$1M
Deployed into pediatric research grants
13K+
Annual visitors · OsteosarcomaNow.org
INVITED TWICE TO THE WHITE HOUSE CANCER MOONSHOT SUMMITS
07 / 10
What we needto move forward.
THE ASK · 07
01
Strategic alignment
Engagement with government stakeholders able to endorse novel public-interest finance.
02
Institutional investors
Dialogue with allocators who can participate at scale within existing mandates.
03
Research partnerships
Collaboration with leading pediatric oncology institutions on portfolio design.
04
Pilot issuance
Support in structuring the first Yellow Bond transaction end-to-end.
05
Innovation mandate
Commitment to novel approaches in public-interest finance at sovereign scale.
08 / 10
THE MODEL · 08 · THE NORWEGIAN BURDEN
Childhood cancer costs NorwayNOK 10.75B per year.
TOTAL ANNUAL BURDEN
10.75
NOK BN · PER YEAR
10-year impact exceeds NOK 100B · conservative floor NOK 6B / year. Methodology builds on the Norwegian Nye Metoder severity framework.
WELFARE · QALY
4.0B
Pain and suffering · QALY loss
PRODUCTIVITY
3.8B
Mortality productivity loss
PRODUCTIVITY
1.5B
Morbidity productivity loss
HEALTHCARE
0.7B
Direct healthcare costs
PRODUCTIVITY
0.5B
Caregiver productivity loss
HEALTHCARE
0.25B
Late-effects treatment
METHODOLOGY
Human-capital method · QALY-based welfare · Prevalence-based healthcare costing
SOURCES
SSB Nasjonalregnskap 2024 · FHI Barnekreft 2024 · Nasjonalt kvalitetsregister for barnekreft · Gunnes et al. 2017 · Nye Metoder severity framework · Helsedirektoratet DRG · CCSS
09 / 10
B
THE BARDO FOUNDATION
LET'S CONNECT · 09
Childhood cancer is not just a medical challenge. It is a capital allocation problem.
The tools already exist. What is missing is execution at scale. The Yellow Bond is a path to unlock it · and Norway is positioned to lead.
EXECUTIVE DIRECTOR
Bjarne Eggesbø The Bardo Foundation · Miami · London · OsloENGLISH
TheBardoFoundation.orgNORWEGIAN
TeamBardo.NoYELLOW BOND
YellowBonds.org10 / 10